# KarMMa (NCT03361748)

> Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03361748
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Multiple Myeloma
- Interventions: bb2121
- Enrollment: 149
- Primary outcome: Overall Response Rate

## Commentary we found

- X threads: 24
- YouTube: 19
- Podcasts: 7

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=karmma-nct03361748

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03361748", "email": "<work email>"}; the inbox owner confirms by the emailed link.